Plus Therapeutics (PSTV) announced two new hires to its team for CNSide Diagnostics, its wholly-owned subsidiary. Two team members joining the CNSide Diagnostics team are: Prem Gurnani joins as Senior Director of Lab Operations and Systems Implementation, Elaine Luckey joins as Director of Quality and Regulatory affairs. In connection with these two new hires, on December 4, 2025, the Company granted stock options and restricted stock units to Gurnani and Luckey under its 2015 New Employee Incentive Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics presents REYOBIQ data at WFNOS/SNO annual meeting
- Strategic Advancements and Market Expansion Drive Plus Therapeutics’ Buy Rating
- Plus Therapeutics completes FDA meeting on REYOBIQ development plans
- Strategic Advancements and Expanding Coverage Propel Plus Therapeutics’ Growth Potential
- Plus Therapeutics’ assay secures national coverage agreement with Humana